Novartis AG said its new drug for multiple sclerosis will have a wholesale price of about $48,000 a year per person in the U.S., making it among the most expensive drugs for the disease.
The Swiss drug giant is launching the treatment, Gilenya, in the U.S. this month.
via online.wsj.com
